Treatment in CARD eligible metastatic castration resistant...

Annals of Oncology 2020 / 09 Vol. 31

Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone

Llacer Perez, C., Romero Laorden, N., Lozano Mejorada, R., Piulats, J.M., Puente, J., Lorente Estelles, D., Medina, A., Cattrini, C., Vitrone, F.M., Almagro, E., Borrega García, P., Lainez, N., River
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.887
Date:
September, 2020
File:
PDF, 109 KB
2020
Conversion to is in progress
Conversion to is failed